Secukinumab for the treatment of residual psoriasis : a case series
Patients with plaque-type psoriasis persisting in limited and critical areas often require further treatment even after a PASI reduction has been obtained. Due to its alternative mechanism of action, secukinumab may be a therapeutic upgrade for patients who respond to anti-TNF-α drug but have persistent disease in limited and critical areas. This paper describes our experience in patients with residual psoriasis limited to critical areas, after anti-TNF-α treatment, who subsequently received secukinumab. Specifically, before secukinumab, 4 patients were treated with acitretin and 8 patients with cyclosporine followed by adalimumab or etanercept. Eleven of 12 patients achieved PASI 90/100 at week 3/5, retaining the effect for 52 weeks of treatment, with irrelevant residual scalp lesions. The non-responder patient had been treated with cyclosporine. Secukinumab improvement was independent from the previous treatment (acitretin vs cyclosporine or adalimumab vs etanercept). Secukinumab may be effective and safe for the treatment of patients with residual psoriasis that still affects the patient's life.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
The Journal of dermatological treatment - 29(2018), sup1 vom: 10., Seite 12-13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Malagoli, Piergiorgio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 08.05.2019 Date Revised 10.12.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/09546634.2018.1524819 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295419504 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295419504 | ||
| 003 | DE-627 | ||
| 005 | 20231225083622.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09546634.2018.1524819 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0984.xml |
| 035 | |a (DE-627)NLM295419504 | ||
| 035 | |a (NLM)30919723 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Malagoli, Piergiorgio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Secukinumab for the treatment of residual psoriasis |b a case series |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.05.2019 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Patients with plaque-type psoriasis persisting in limited and critical areas often require further treatment even after a PASI reduction has been obtained. Due to its alternative mechanism of action, secukinumab may be a therapeutic upgrade for patients who respond to anti-TNF-α drug but have persistent disease in limited and critical areas. This paper describes our experience in patients with residual psoriasis limited to critical areas, after anti-TNF-α treatment, who subsequently received secukinumab. Specifically, before secukinumab, 4 patients were treated with acitretin and 8 patients with cyclosporine followed by adalimumab or etanercept. Eleven of 12 patients achieved PASI 90/100 at week 3/5, retaining the effect for 52 weeks of treatment, with irrelevant residual scalp lesions. The non-responder patient had been treated with cyclosporine. Secukinumab improvement was independent from the previous treatment (acitretin vs cyclosporine or adalimumab vs etanercept). Secukinumab may be effective and safe for the treatment of patients with residual psoriasis that still affects the patient's life | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a residual psoriasis reduction | |
| 650 | 4 | |a secukinumab | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Dermatologic Agents |2 NLM | |
| 650 | 7 | |a secukinumab |2 NLM | |
| 650 | 7 | |a DLG4EML025 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of dermatological treatment |d 1992 |g 29(2018), sup1 vom: 10., Seite 12-13 |w (DE-627)NLM088851680 |x 1471-1753 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2018 |g number:sup1 |g day:10 |g pages:12-13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09546634.2018.1524819 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2018 |e sup1 |b 10 |h 12-13 | ||